Clementia is a privately-held, clinical stage biotechnology company dedicated to the development and commercialization of treatments for people living with rare diseases. Clementia exploits the use of novel Retinoic acid receptor gamma agonists (RARγ) to address diseases of heterotopic ossification, including Fibrodysplasia Ossificans Progressiva.
Clementia is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.
Jean-François Pariseau, Founding Partner at Amplitude Venture Capital
Investment year: 2012
Industry sector: Drugs
Canada’s biotech sector continues to build momentum with two large IPOs since March